

# Nplate™ NEXUS Program Fact Sheet



## AMGEN CONTACT INFORMATION

Media: 805-447-5631

[plange@amgen.com](mailto:plange@amgen.com)

Investor Relations: 805-447-1060

[Investor.relations@amgen.com](mailto:Investor.relations@amgen.com)

### Nplate™ NEXUS Program Enrollment

More information about Nplate™, including the full prescribing information, medication guide and the Nplate™ NEXUS Program is available by calling 1-877-NPLATE1 (877-675-2831), or by visiting [www.nplate.com](http://www.nplate.com)

## What is the Nplate™ NEXUS Program?

The Nplate™ NEXUS Program (**Network of EXperts Understanding and Supporting Nplate™ and Patients**) is a multi-faceted program designed to provide comprehensive access, support and education for chronic ITP patients, their caregivers and healthcare providers. The Nplate™ NEXUS Program is part of the Risk Evaluation and Mitigation Strategies (REMS) program that Amgen developed in partnership with the FDA to assure safe use of Nplate™ while minimizing risk. The program aims to educate both patients and healthcare professionals about Nplate™ (romiplostim), to help facilitate doctor/patient dialogue about the benefits and risks of Nplate™ treatment, and to provide necessary resources and aid to support the appropriate use of this novel medication.

Additionally, eligible patients who are uninsured, underinsured, or unable to afford their insurance co-payments may be able to receive reimbursement support and other assistance from Amgen through the Nplate™ NEXUS Program. For example, one such program helps cover up to 50 percent of an eligible, commercially-insured patient's co-payments for Nplate™. Recognizing that some patients may not have healthcare coverage, Amgen continues to offer another program for all of its innovative products, including Nplate™, which provides product free of charge to eligible, low-income patients without insurance.

## What does the Nplate™ NEXUS Program Include?

The Nplate™ NEXUS Program includes the following components:

- **Product Distribution:** The Nplate™ NEXUS Program is designed to facilitate access and distribution of Nplate™ to healthcare providers. After enrollment, healthcare providers will be able to order Nplate through their regular fulfillment channels. The Nplate™ NEXUS program is designed to ensure program compliance and facilitate distribution. As needed or in the case of an emergency, Nplate™ can always be ordered and shipped within 24 hours for patients enrolled in the Nplate™ NEXUS program by contacting the program directly.
- **Physician and Patient Education Tools:** The Nplate™ NEXUS Program includes healthcare provider education and training kits to assist practitioners prescribing Nplate™ understand the benefits/risks of treatment, facilitate patient enrollment, and track patient progress. Specific patient education tools include a medication guide to educate and help patients manage their Nplate™ treatment.
- **Ongoing Safety Data Collection:** The Nplate™ NEXUS Program includes a patient safety registry which is designed to help track and monitor adverse events, and long term safety information. Follow up information will be collected every six months and at treatment discontinuation through a questionnaire.
- **24-Hour Patient Support:** The Nplate™ NEXUS Program specialists and reimbursement specialists will be available from 8:00 am to 8:00 pm Eastern Standard Time to answer any questions about Nplate™ therapy, support programs, or insurance issues, however, the phone line will be open 24 hours a day.

## Nplate™ Patient Assistance Programs

Amgen is dedicated to providing comprehensive access for patients receiving Nplate™, and has created several **Nplate™ Patient Assistance Programs** to meet the varying needs of chronic ITP patients. Through these programs, eligible patients who are uninsured, underinsured, or unable to afford their insurance co-payments may be able to receive reimbursement support and other assistance from Amgen.

The key components of this program include:

Program	Insured	Under-insured	Uninsured	Description	Qualifications
<b>SAFETYNET® Foundation</b>			✓	Foundation provides financial support for Nplate™ patients who are uninsured with a household annual income of less than \$75,000 per year.	For patients who are uninsured with a household annual income of less than \$75,000 per year.  Enrollment in Nplate™ NEXUS Program.
<b>Independent Co-Pay Assistance (Medicare and/or commercially insured)</b>	✓	✓		Independent, third-party co-pay foundations provide financial support for the insured and under-insured. Amgen makes donations to these foundations to assist eligible patients with co-insurance and co-payment obligations.	Enrollment in Nplate™ NEXUS Program.
<b>“Share” Program (Commercially insured)</b>	✓	✓		This program offers financial assistance of up to 50% of a commercially-insured Nplate™ patient’s co-insurance and co-payment obligations.	For patients with an annual adjusted gross income of less than four times the federal poverty level (FPL).  Enrollment of Nplate™ NEXUS Program.

\*All programs for adult chronic ITP patients

\*Four times FPL: \$41K for an individual, \$55K for family of 2, \$69K for family of 3, \$83K for family of 4

## Nplate™ Indication

Nplate™ is indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate™ should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate™ should not be used in an attempt to normalize platelet counts.

## Important Safety Information

Serious adverse reactions associated with Nplate in clinical studies were bone marrow reticulin deposition and worsening thrombocytopenia after Nplate discontinuation. Additional risks include Bone Marrow Fibrosis, Thrombotic/Thromboembolic Complications, Lack or Loss of Response to Nplate, and Hematological Malignancies and Progression of Malignancy in Patients with a Pre-existing Hematological Malignancy or Myelodysplastic Syndrome (MDS).

Nplate is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Nplate™ is available only through a restricted distribution program called Nplate™ NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program.

In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

###